HaemaLogiX has strategic research partnerships with leading global cancer institutes, hospitals and cell therapy companies to progress the clinical development of its immunotherapies in multiple myeloma and related diseases.
In 2023, HaemaLogiX entered into a strategic partnership with Peter Mac to initiate a Phase 1 clinical trial of a KMA-targeted CAR-T cell therapy in patients with relapsed or refractory kappa-type multiple myeloma. This collaboration provides the Company with access to world-class clinical and manufacturing expertise and advanced cell therapy infrastructure located at Peter Mac. The Phase 1 trial is expected to generate early human proof-of-concept for HaemaLogiX’s highly targeted immunotherapy approach.
Building on this agreement, in March 2025, HaemaLogiX entered into a pre-clinical research agreement with Immuneel Therapeutics Private Limited (Immuneel), a leading immuno-oncology company, to evaluate the potential of KMA in CAR-T applications. This agreement is anticipated to enable the Company to leverage Immuneel’s capabilities in cell therapy innovation and manufacturing.
HaemaLogiX has a contract manufacturing agreement with Lonza, a global leader in biologics manufacturing, to support the ongoing development and production of KappaMab. Lonza is one of the world’s leading Contract Development and Manufacturing Organisations, specialising in monoclonal antibody production, with GMP-certified facilities that meet the strict requirements of regulatory agencies like the FDA, EMA, and TGA and will enable scalable clinical and commercial programs.